RLFT.Y Stock Overview
Relief Therapeutics Holding AG, a biopharmaceutical company, focuses on identification, development, and commercialization of novel, patent protected products for the treatment of metabolic, dermatological, and pulmonary rare diseases in Switzerland, Europe, North America, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Relief Therapeutics Holding SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF1.37 |
| 52 Week High | CHF4.19 |
| 52 Week Low | CHF1.37 |
| Beta | -14.15 |
| 1 Month Change | -2.54% |
| 3 Month Change | n/a |
| 1 Year Change | -83.27% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -96.59% |
Recent News & Updates
Recent updates
Shareholder Returns
| RLFT.Y | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -2.5% | -1.6% | 1.6% |
| 1Y | -83.3% | 2.8% | 26.2% |
Return vs Industry: RLFT.Y underperformed the US Biotechs industry which returned 3.4% over the past year.
Return vs Market: RLFT.Y underperformed the US Market which returned 26% over the past year.
Price Volatility
| RLFT.Y volatility | |
|---|---|
| RLFT.Y Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: RLFT.Y's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine RLFT.Y's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 69 | Michelle Lock | www.relieftherapeutics.com |
Relief Therapeutics Holding AG, a biopharmaceutical company, focuses on identification, development, and commercialization of novel, patent protected products for the treatment of metabolic, dermatological, and pulmonary rare diseases in Switzerland, Europe, North America, and internationally. The company offers SETOFILM/ONDISSOLVE for radiotherapy induced nausea and vomiting, and chemotherapy induced nausea and vomiting, as well as postoperative induced nausea and vomiting. It develops RLF-100, a synthetic form of vasoactive intestinal peptide (VIP) for the treatment of acute respiratory distress syndrome (ARDS) associated with COVID-19, nonCOVID-19-related ARDS, pulmonary sarcoidosis, checkpoint inhibitor-induced pneumonitis, and chronic berylliosis.
Relief Therapeutics Holding SA Fundamentals Summary
| RLFT.Y fundamental statistics | |
|---|---|
| Market cap | US$17.29m |
| Earnings (TTM) | -US$108.32m |
| Revenue (TTM) | US$6.98m |
2.4x
P/S Ratio-0.2x
P/E RatioIs RLFT.Y overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RLFT.Y income statement (TTM) | |
|---|---|
| Revenue | CHF6.33m |
| Cost of Revenue | CHF1.74m |
| Gross Profit | CHF4.59m |
| Other Expenses | CHF102.77m |
| Earnings | -CHF98.18m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -7.83 |
| Gross Margin | 72.57% |
| Net Profit Margin | -1,551.53% |
| Debt/Equity Ratio | 0.7% |
How did RLFT.Y perform over the long term?
See historical performance and comparison